JP2018528774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528774A5 JP2018528774A5 JP2018512998A JP2018512998A JP2018528774A5 JP 2018528774 A5 JP2018528774 A5 JP 2018528774A5 JP 2018512998 A JP2018512998 A JP 2018512998A JP 2018512998 A JP2018512998 A JP 2018512998A JP 2018528774 A5 JP2018528774 A5 JP 2018528774A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- protein
- cells
- immune cell
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021075261A JP7298103B2 (ja) | 2015-09-09 | 2021-04-27 | 免疫療法のためのマクロファージの遺伝子組換え |
| JP2023086702A JP2023109956A (ja) | 2015-09-09 | 2023-05-26 | 免疫療法のためのマクロファージの遺伝子組換え |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216224P | 2015-09-09 | 2015-09-09 | |
| US62/216,224 | 2015-09-09 | ||
| US201662361348P | 2016-07-12 | 2016-07-12 | |
| US62/361,348 | 2016-07-12 | ||
| PCT/US2016/050552 WO2017044487A1 (en) | 2015-09-09 | 2016-09-07 | Genetic engineering of macrophages for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021075261A Division JP7298103B2 (ja) | 2015-09-09 | 2021-04-27 | 免疫療法のためのマクロファージの遺伝子組換え |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018528774A JP2018528774A (ja) | 2018-10-04 |
| JP2018528774A5 true JP2018528774A5 (enExample) | 2019-10-24 |
| JP6959909B2 JP6959909B2 (ja) | 2021-11-05 |
Family
ID=58240865
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512998A Active JP6959909B2 (ja) | 2015-09-09 | 2016-09-07 | 免疫療法のためのマクロファージの遺伝子組換え |
| JP2021075261A Active JP7298103B2 (ja) | 2015-09-09 | 2021-04-27 | 免疫療法のためのマクロファージの遺伝子組換え |
| JP2023086702A Pending JP2023109956A (ja) | 2015-09-09 | 2023-05-26 | 免疫療法のためのマクロファージの遺伝子組換え |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021075261A Active JP7298103B2 (ja) | 2015-09-09 | 2021-04-27 | 免疫療法のためのマクロファージの遺伝子組換え |
| JP2023086702A Pending JP2023109956A (ja) | 2015-09-09 | 2023-05-26 | 免疫療法のためのマクロファージの遺伝子組換え |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10525082B2 (enExample) |
| EP (1) | EP3347026A4 (enExample) |
| JP (3) | JP6959909B2 (enExample) |
| CN (1) | CN108243607A (enExample) |
| AU (1) | AU2016318773B2 (enExample) |
| CA (1) | CA2997912A1 (enExample) |
| HK (1) | HK1257460A1 (enExample) |
| SG (1) | SG10201913151TA (enExample) |
| WO (1) | WO2017044487A1 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| GB201418965D0 (enExample) | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| US10525082B2 (en) * | 2015-09-09 | 2020-01-07 | Seattle Children's Hospital | Genetic engineering of macrophages for immunotherapy |
| MY194135A (en) | 2016-02-04 | 2022-11-14 | Zhenglun Zhu | Treatment and diagnosis of inflammatory disorders |
| EP4212169A1 (en) | 2016-03-25 | 2023-07-19 | PeriphaGen, Inc. | High-transducing hsv vectors |
| US12144850B2 (en) | 2016-04-08 | 2024-11-19 | Purdue Research Foundation | Methods and compositions for car T cell therapy |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| EP3601539A4 (en) * | 2017-03-28 | 2021-01-13 | Zhenglun Zhu | METHODS OF TREATING NEOPLASIC DISEASES |
| JP2020516654A (ja) * | 2017-04-13 | 2020-06-11 | センティ バイオサイエンシズ インコーポレイテッド | 組み合わせがん免疫療法 |
| CN110913871B (zh) * | 2017-05-17 | 2024-02-23 | 西雅图儿童医院（Dba西雅图儿童研究所） | 生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法 |
| JP7097438B2 (ja) | 2017-07-11 | 2022-07-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
| CN111527209B (zh) * | 2017-11-01 | 2024-11-12 | 爱迪塔斯医药股份有限公司 | Crispr-cas9编辑t细胞中的tgfbr2以用于免疫疗法的方法、组合物和组分 |
| EP3710016A4 (en) * | 2017-11-17 | 2021-12-01 | Memorial Sloan-Kettering Cancer Center | METHODS AND COMPOSITIONS FOR RELIEVING CYTOCINE RELEASE SYNDROME |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| CA3091674A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| WO2019195420A1 (en) | 2018-04-04 | 2019-10-10 | Nant Holding IP, LLC | Advanced avartar dendritic cells |
| CA3291067A1 (en) * | 2018-04-12 | 2025-11-29 | Kite Pharma, Inc. | Chimeric receptor t cell treatment using characteristics of the tumor microenvironment |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| GB2587970B (en) | 2018-04-19 | 2023-02-08 | Univ California | Compositions and methods for gene editing |
| US12410231B2 (en) | 2018-05-07 | 2025-09-09 | Board Of Regents Of The University Of Texas System | Natural killer cell products and methods |
| EP3820485A4 (en) | 2018-05-15 | 2022-05-11 | The Brigham & Women's Hospital, Inc. | COMPOSITIONS AND METHODS RELATED TO TUMOR CELL KILLERS AND VACCINES |
| US20210254068A1 (en) * | 2018-06-19 | 2021-08-19 | Regents Of The University Of Minnesota | Genome engineering primary monocytes |
| JP7340591B2 (ja) | 2018-07-11 | 2023-09-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
| CN108823171A (zh) * | 2018-07-24 | 2018-11-16 | 武汉赛云博生物科技有限公司 | 一种基因工程细胞及体外高效扩增nk细胞的方法 |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| GB201818110D0 (en) * | 2018-11-06 | 2018-12-19 | Macrophox Ltd | Monocytes for cancer targeting |
| EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| AU2019384145A1 (en) * | 2018-11-20 | 2021-06-10 | Innovative Cellular Therapeutics Holdings, Ltd. | Modified cell expressing therapeutic agent and uses thereof |
| US20220056479A1 (en) * | 2018-12-17 | 2022-02-24 | Cure Genetics Co., Ltd. | Method For Delivering Gene In Cells |
| CN113508178A (zh) * | 2019-02-01 | 2021-10-15 | 西雅图儿童医院（Dba西雅图儿童研究所） | 用于调节经工程化的基因的表达的微环境传感器 |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| CA3131017C (en) * | 2019-02-27 | 2025-05-13 | Actym Therapeutics, Inc. | Immunostimulatory bacteria modified to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| JP2022531814A (ja) * | 2019-03-12 | 2022-07-12 | イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ | 改変細胞の増幅およびその応用 |
| CA3135165A1 (en) * | 2019-03-28 | 2020-10-01 | Sierra Oncology, Inc. | Methods of treating cancer with chk1 inhibitors |
| US11013764B2 (en) | 2019-04-30 | 2021-05-25 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| CN110760480B (zh) * | 2019-07-09 | 2021-07-02 | 杭州师范大学 | 一种抗肿瘤nk细胞及其制备方法 |
| KR20220097875A (ko) | 2019-09-03 | 2022-07-08 | 마이얼로이드 테라퓨틱스, 인크. | 게놈 통합을 위한 방법 및 조성물 |
| JP2022548069A (ja) * | 2019-09-11 | 2022-11-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | キメラ直交受容体タンパク質および使用方法 |
| BR112022005044A2 (pt) * | 2019-09-17 | 2022-07-05 | Ohio State Innovation Foundation | Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento |
| WO2021064655A1 (en) * | 2019-10-02 | 2021-04-08 | Massachusetts Institute Of Technology | High-throughput genetic screening |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| CN111150748A (zh) * | 2019-12-27 | 2020-05-15 | 杭州荣谷生物科技有限公司 | 重组溶瘤病毒在制备治疗消化道癌药物中的用途 |
| CN111087460B (zh) * | 2020-01-14 | 2021-07-30 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 一种广谱型抗菌肽及其应用 |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| MX2022011673A (es) | 2020-03-20 | 2022-12-13 | Lyell Immunopharma Inc | Nuevos marcadores de superficie celular recombinantes. |
| TW202204348A (zh) | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Ｃｈｋ１抑制劑之合成方法 |
| GB202007906D0 (en) | 2020-05-27 | 2020-07-08 | Univ Edinburgh | Method of transfecting macrophages |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| KR20230042691A (ko) | 2020-06-04 | 2023-03-29 | 카리스마 테라퓨틱스 인코포레이티드 | 키메라 항원 수용체에 대한 신규한 작제물 |
| EP4189074A4 (en) * | 2020-06-22 | 2025-01-15 | Nanjing Legend Biotech Co., Ltd. | GENETICALLY MODIFIED GAMMA DELTA T CELLS FOR IMMUNOTHERAPY |
| JP2023549140A (ja) | 2020-11-04 | 2023-11-22 | マイエロイド・セラピューティクス，インコーポレーテッド | 操作されたキメラ融合タンパク質組成物およびその使用方法 |
| WO2022165260A1 (en) * | 2021-01-29 | 2022-08-04 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
| CA3172530A1 (en) | 2021-02-25 | 2022-09-01 | Spencer PARK | Ror1 targeting chimeric antigen receptor |
| KR20240013094A (ko) | 2021-03-17 | 2024-01-30 | 마이얼로이드 테라퓨틱스, 인크. | 조작된 키메라 융합 단백질 조성물 및 그의 사용 방법 |
| BR112023023642A2 (pt) | 2021-05-11 | 2024-01-30 | Myeloid Therapeutics Inc | Métodos e composições para integração genômica |
| JP2024527593A (ja) * | 2021-07-09 | 2024-07-25 | レジェンド バイオテック アイルランド リミテッド | 変異型ｉｌ－１５組成物及びその方法 |
| WO2023053828A1 (ja) * | 2021-09-30 | 2023-04-06 | テルモ株式会社 | 化学療法制御装置、化学療法制御システム、化学療法制御装置の制御方法及び化学療法制御プログラム |
| US20250000974A1 (en) * | 2021-10-27 | 2025-01-02 | The Regents Of The University Of California | Combination of human natural killer cells and macrophages for cancer therapy |
| CN114404600B (zh) * | 2022-01-21 | 2023-06-27 | 首都医科大学附属北京同仁医院 | 一种用于治疗肿瘤的药物组合及其应用 |
| CN114657143B (zh) * | 2022-03-11 | 2022-10-25 | 西安电子科技大学 | 一种肿瘤微环境调控型car-单核/巨噬细胞及其制备方法和应用 |
| WO2023205661A2 (en) * | 2022-04-18 | 2023-10-26 | Candel Therapeutics, Inc. | Compositions and methods for viral vectors |
| WO2023205657A2 (en) * | 2022-04-18 | 2023-10-26 | City Of Hope | Compositions for restoring mecp2 gene function and methods of use thereof |
| WO2024215990A2 (en) * | 2023-04-13 | 2024-10-17 | William Marsh Rice University | Regulated cells expressing cytokines |
| WO2025251079A1 (en) * | 2024-05-31 | 2025-12-04 | University Of Massachusetts | Rna compositions and methods of use thereof in the treatment of cancer |
| WO2026062037A1 (en) | 2024-09-18 | 2026-03-26 | Myllia Biotechnology Gmbh | Gene perturbation in human monocyte-derived macrophages |
| WO2026069312A1 (en) | 2024-09-24 | 2026-04-02 | Yeda Research And Development Co. Ltd. | Immune cells expressing an inducible therapeutic agent and uses thereof |
| CN119020422A (zh) * | 2024-10-28 | 2024-11-26 | 昆明医科大学 | 一种稳转萤火虫萤光素酶靶细胞株的构建方法及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998046083A1 (en) * | 1997-04-17 | 1998-10-22 | The Regents Of The University Of California | Use of lentiviral vectors for antigen presentation in dendritic cells |
| US7432351B1 (en) * | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
| IN2014DN06624A (enExample) * | 2005-10-18 | 2015-07-10 | Univ Colorado | |
| US7919079B2 (en) * | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| US9023648B2 (en) * | 2009-12-30 | 2015-05-05 | University Of Massachusetts | Method of transducing non-dividing myeloid cells utilizing chimeric murine leukemia viruses containing Vpx |
| MX342017B (es) | 2010-03-26 | 2016-09-09 | Dartmouth College | Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos. |
| US9987308B2 (en) | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| EP2755487B1 (en) | 2011-09-16 | 2018-12-19 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| EP3594245A1 (en) * | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| US8323662B1 (en) * | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
| US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
| PL3824905T3 (pl) * | 2012-08-20 | 2025-05-05 | Fred Hutchinson Cancer Center | Sposób i kompozycje do immunoterapii komórkowej |
| EP3763810A3 (en) * | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| HK1219980A1 (zh) * | 2013-03-09 | 2017-04-21 | Baylor College Of Medicine | 靶向血管的t细胞疗法 |
| US9587032B2 (en) * | 2013-06-12 | 2017-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | IgE antibodies for the inhibition of tumor metastasis |
| ES2792849T3 (es) | 2014-02-10 | 2020-11-12 | Univ Emory | Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer |
| CN108025024B (zh) | 2015-07-28 | 2022-11-29 | 宾夕法尼亚大学董事会 | 表达嵌合抗原受体的修饰单核细胞/巨噬细胞及其用途 |
| US11352439B2 (en) | 2015-08-13 | 2022-06-07 | Kim Leslie O'Neill | Macrophage CAR (MOTO-CAR) in immunotherapy |
| US10525082B2 (en) | 2015-09-09 | 2020-01-07 | Seattle Children's Hospital | Genetic engineering of macrophages for immunotherapy |
-
2016
- 2016-09-07 US US15/258,887 patent/US10525082B2/en active Active
- 2016-09-07 JP JP2018512998A patent/JP6959909B2/ja active Active
- 2016-09-07 CA CA2997912A patent/CA2997912A1/en active Pending
- 2016-09-07 CN CN201680065510.4A patent/CN108243607A/zh active Pending
- 2016-09-07 WO PCT/US2016/050552 patent/WO2017044487A1/en not_active Ceased
- 2016-09-07 EP EP16844978.3A patent/EP3347026A4/en active Pending
- 2016-09-07 HK HK18116695.4A patent/HK1257460A1/zh unknown
- 2016-09-07 AU AU2016318773A patent/AU2016318773B2/en active Active
- 2016-09-07 SG SG10201913151TA patent/SG10201913151TA/en unknown
-
2019
- 2019-11-25 US US16/694,024 patent/US11826384B2/en active Active
-
2021
- 2021-04-27 JP JP2021075261A patent/JP7298103B2/ja active Active
-
2023
- 2023-05-26 JP JP2023086702A patent/JP2023109956A/ja active Pending
- 2023-10-17 US US18/488,400 patent/US20240091256A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021118723A5 (enExample) | ||
| Audsley et al. | Cross-presenting XCR1+ dendritic cells as targets for cancer immunotherapy | |
| Del Prete et al. | Functional role of dendritic cell subsets in cancer progression and clinical implications | |
| Halin et al. | Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature | |
| Card et al. | A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity | |
| JP2023053110A (ja) | キメラ抗原受容体、組成物及び方法 | |
| Kang et al. | Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+ T cells in the tumor loci and enhanced anti-tumor effects | |
| Hashimoto et al. | Type I IFN gene delivery suppresses regulatory T cells within tumors | |
| JP2018522567A5 (enExample) | ||
| Lucarini et al. | Dendritic cells: behind the scenes of T-cell infiltration into the tumor microenvironment | |
| JP2017525364A5 (enExample) | ||
| Benoit et al. | Lighting up the fire in the microenvironment of cold tumors: A major challenge to improve cancer immunotherapy | |
| JP2023501539A5 (enExample) | ||
| Shimizu et al. | Invariant NKT cells induce plasmacytoid dendritic cell (DC) cross-talk with conventional DCs for efficient memory CD8+ T cell induction | |
| Wahid et al. | An overview of cancer immunotherapeutic strategies | |
| Biegert et al. | Current development in adenoviral vectors for cancer immunotherapy | |
| Shen et al. | Tumor-associated macrophages, dendritic cells, and neutrophils: biological roles, crosstalk, and therapeutic relevance | |
| CN112426438A (zh) | 用于调控酸性环境免疫应答的组合物、其制备方法和用途 | |
| JP2019509715A5 (enExample) | ||
| Rossari et al. | Gene-based delivery of immune-activating cytokines for cancer treatment | |
| Bobanga et al. | Chemokines as cancer vaccine adjuvants | |
| JP2021511060A5 (enExample) | ||
| JP2020511139A5 (enExample) | ||
| JP2022513412A5 (enExample) | ||
| Borgers et al. | Cellular therapy and cytokine treatments for melanoma |